Compare Stocks: CODX, EVAX, CNTX, and RNAZ

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNTX Context Therapeutics	$0.32 -2.2%	$0.46	$0.31 ▼ $3.62	$29.98M	1.69	1.16 million shs	849,428 shs
CODX Co-Diagnostics	$1.07 -3.6%	$1.32	$0.91 ▼ $46.50	$7.75M	2.85	254,225 shs	98,591 shs
EVAX Evaxion A/S	$3.27 +0.9%	$3.11	$2.77 ▼ $12.15	$29.23M	0.26	44,501 shs	38,135 shs
RNAZ TransCode Therapeutics	$1.63 -4.7%	$3.04	$1.58 ▼ $20.99	$28.95M	1.16	54,499 shs	11,006 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNTX Context Therapeutics	-2.24%	-18.02%	-16.86%	-47.56%	-67.07%
CODX Co-Diagnostics	-3.60%	-0.93%	-11.57%	-65.26%	-90.36%
EVAX Evaxion A/S	+0.93%	0.00%	+8.64%	+2.19%	-13.95%
RNAZ TransCode Therapeutics	-4.68%	-7.91%	-25.23%	-78.69%	-84.66%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNTX Context Therapeutics	$0.32 -2.2%	$0.46	$0.31 ▼ $3.62	$29.98M	1.69	1.16 million shs	849,428 shs
CODX Co-Diagnostics	$1.07 -3.6%	$1.32	$0.91 ▼ $46.50	$7.75M	2.85	254,225 shs	98,591 shs
EVAX Evaxion A/S	$3.27 +0.9%	$3.11	$2.77 ▼ $12.15	$29.23M	0.26	44,501 shs	38,135 shs
RNAZ TransCode Therapeutics	$1.63 -4.7%	$3.04	$1.58 ▼ $20.99	$28.95M	1.16	54,499 shs	11,006 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNTX Context Therapeutics	-2.24%	-18.02%	-16.86%	-47.56%	-67.07%
CODX Co-Diagnostics	-3.60%	-0.93%	-11.57%	-65.26%	-90.36%
EVAX Evaxion A/S	+0.93%	0.00%	+8.64%	+2.19%	-13.95%
RNAZ TransCode Therapeutics	-4.68%	-7.91%	-25.23%	-78.69%	-84.66%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CNTX Context Therapeutics	2.70	Moderate Buy	$6.17	1,833.12% Upside
CODX Co-Diagnostics	2.50	Moderate Buy	$67.50	6,208.41% Upside
EVAX Evaxion A/S	2.67	Moderate Buy	$11.00	236.39% Upside
RNAZ TransCode Therapeutics	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest CODX, EVAX, CNTX, and RNAZ Analyst Ratings

Date	Company	Brokerage	Action	Rating
9/8/2026	CODX Co-Diagnostics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/3/2026	CNTX Context Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/20/2026	CNTX Context Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/18/2026	CODX Co-Diagnostics	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/6/2026	CNTX Context Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
8/6/2026	CNTX Context Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/6/2026	CNTX Context Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/17/2026	CNTX Context Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	RNAZ TransCode Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/9/2026	EVAX Evaxion A/S	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CNTX Context Therapeutics	N/A	N/A	N/A	N/A	$0.66 per share	N/A
CODX Co-Diagnostics	$721.39K	10.35	N/A	N/A	$9.14 per share	0.12
EVAX Evaxion A/S	$7.53M	3.92	N/A	N/A	$2.04 per share	1.60
RNAZ TransCode Therapeutics	N/A	N/A	N/A	N/A	$11.27 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CNTX Context Therapeutics	-$36.12M	-$0.48	N/A	N/A	N/A	N/A	-82.06%	-72.74%	11/4/2026 (Estimated)
CODX Co-Diagnostics	-$46.90M	-$10.32	N/A	N/A	N/A	-6,531.77%	-210.99%	-174.97%	11/5/2026 (Estimated)
EVAX Evaxion A/S	-$7.71M	-$1.21	N/A	N/A	N/A	N/A	-61.43%	-34.23%	11/5/2026 (Estimated)
RNAZ TransCode Therapeutics	-$34.66M	-$52.37	N/A	N/A	N/A	N/A	-875.35%	-37.46%	11/18/2026 (Estimated)

Latest CODX, EVAX, CNTX, and RNAZ Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	RNAZ TransCode Therapeutics	N/A	-$7.17	N/A	-$7.17	N/A	N/A
8/13/2026	Q2 2026	CODX Co-Diagnostics	-$3.00	-$1.46	+$1.54	-$1.46	$0.13 million	$0.17 million
8/5/2026	Q2 2026	CNTX Context Therapeutics	-$0.0921	-$0.15	-$0.0579	-$0.15	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CNTX Context Therapeutics	N/A	N/A	N/A	N/A	N/A
CODX Co-Diagnostics	N/A	N/A	N/A	N/A	N/A
EVAX Evaxion A/S	N/A	N/A	N/A	N/A	N/A
RNAZ TransCode Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CNTX Context Therapeutics	N/A	5.81	5.81
CODX Co-Diagnostics	N/A	1.81	1.52
EVAX Evaxion A/S	0.69	5.06	5.06
RNAZ TransCode Therapeutics	N/A	1.97	1.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CNTX Context Therapeutics	14.03%
CODX Co-Diagnostics	14.99%
EVAX Evaxion A/S	11.04%
RNAZ TransCode Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
CNTX Context Therapeutics	4.80%
CODX Co-Diagnostics	2.30%
EVAX Evaxion A/S	41.64%
RNAZ TransCode Therapeutics	0.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CNTX Context Therapeutics	15	91.88 million	87.47 million	Not Optionable
CODX Co-Diagnostics	115	6.98 million	6.82 million	No Data
EVAX Evaxion A/S	46	9.02 million	5.27 million	No Data
RNAZ TransCode Therapeutics	12	16.93 million	16.91 million	Not Optionable

CODX, EVAX, CNTX, and RNAZ Headlines

Recent News About These Companies

TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up

September 28 at 8:04 AM | prnewswire.com

TransCode Therapeutics Announces Patent Advancements in Australia and Japan Strengthening Global IP Position in RNA-Based Immuno-Oncology

September 22, 2026 | prnewswire.com

TransCode Therapeutics, Inc. (RNAZ) Discusses Advancing Multi-Platform Oncology Pipeline Targeting Metastatic Cancer Transcript

September 16, 2026 | seekingalpha.com

Join Today’s Live Investor Webinar with TransCode Therapeutics

September 16, 2026 | usatoday.com

TransCode Therapeutics Announces Leadership Transition

September 10, 2026 | prnewswire.com

Join TransCode Therapeutics’ Live Investor Webinar: Advancing a Multi-Platform Oncology Pipeline Targeting Metastatic Cancer

September 3, 2026 | usatoday.com

TransCode Therapeutics Announces Publication Demonstrating Survival Benefit of TTX-MC138 in Preclinical Model of Breast Cancer Bone Metastasis

August 31, 2026 | prnewswire.com

Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV

August 7, 2026 | finance.yahoo.com

TransCode Therapeutics, Inc.

July 22, 2026 | edition.cnn.com

TransCode Therapeutics Inc RNAZ

July 3, 2026 | morningstar.comM

TransCode Therapeutics, Inc. (RNAZ) Discusses Strategic, Scientific, and Clinical Updates With Focus on TTX-MC138 Phase 2a Trial in Colorectal Cancer Prepared Remarks Transcript

June 18, 2026 | seekingalpha.com

RNAZ: Introducing RNA therapeutics

June 8, 2026 | msn.com

TransCode Therapeutics to Host R&D Webcast on June 18, 2026

June 8, 2026 | prnewswire.com

RNAZ Share News Today

June 4, 2026 | uk.investing.com

EXCLUSIVE: TransCode's RNA Therapeutic Achieves 64% Stable Disease Rate In Colorectal Cancer Phase 1 Study

June 3, 2026 | finance.yahoo.com

TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer

June 3, 2026 | prnewswire.com

TransCode Therapeutics, Inc.: TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer

May 28, 2026 | finanznachrichten.de

TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer

May 27, 2026 | prnewswire.com

TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University

April 27, 2026 | prnewswire.com

TransCode Therapeutics signs financing deal worth up to $20 million

April 8, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CODX, EVAX, CNTX, and RNAZ Company Descriptions

Context Therapeutics NASDAQ:CNTX

$0.32 -0.01 (-2.24%)

Closing price 09/29/2026 04:00 PM Eastern

Extended Trading

$0.34 +0.02 (+6.90%)

As of 04:25 AM Eastern

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Co-Diagnostics NASDAQ:CODX

$1.07 -0.04 (-3.60%)

Closing price 09/29/2026 04:00 PM Eastern

Extended Trading

$1.08 +0.01 (+0.65%)

As of 04:37 AM Eastern

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Evaxion A/S NASDAQ:EVAX

$3.27 +0.03 (+0.93%)

Closing price 09/29/2026 04:00 PM Eastern

Extended Trading

$3.30 +0.03 (+0.92%)

As of 04:42 AM Eastern

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.

TransCode Therapeutics NASDAQ:RNAZ

$1.63 -0.08 (-4.68%)

Closing price 09/29/2026 04:00 PM Eastern

Extended Trading

$1.66 +0.03 (+1.53%)

As of 04:42 AM Eastern

TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CODX, EVAX, CNTX, and RNAZ Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CODX, EVAX, CNTX, and RNAZ Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CODX, EVAX, CNTX, and RNAZ Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CODX, EVAX, CNTX, and RNAZ Company Descriptions

Context Therapeutics NASDAQ:CNTX

Co-Diagnostics NASDAQ:CODX

Evaxion A/S NASDAQ:EVAX

TransCode Therapeutics NASDAQ:RNAZ

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CODX, EVAX, CNTX, and RNAZ Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CODX, EVAX, CNTX, and RNAZ Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CODX, EVAX, CNTX, and RNAZ Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CODX, EVAX, CNTX, and RNAZ Company Descriptions

Context Therapeutics NASDAQ:CNTX

Co-Diagnostics NASDAQ:CODX

Evaxion A/S NASDAQ:EVAX

TransCode Therapeutics NASDAQ:RNAZ

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools